The impact of communicating genetic risks of disease on riskreducing health behaviour: Systematic review with meta-analysis

BMJ (Online)

Volumn 352, Issue , 2016, Pages

  Hollands, Gareth J ^a   French, David P ^b   Griffin, Simon J ^a   Prevost, A Toby ^c   Sutton, Stephen ^a   King, Sarah ^a   Marteau, Theresa M ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL CONSUMPTION; ALZHEIMER DISEASE; ANXIETY; ARTICLE; BEHAVIOR; BEHAVIOR CHANGE; BEHAVIORAL SUPPORT PROGRAM; CANCER RISK; DEPRESSION; DIET; DISEASE RISK; DNA BASED RISK; DRUG USE; ERROR; EVIDENCE BASED MEDICINE; GENETIC RISK; GENETIC SCREENING; GENETIC VARIABILITY; GENOTYPE; HEALTH BEHAVIOR; HEALTH PROGRAM; HUMAN; INTERPERSONAL COMMUNICATION; MOTIVATION; PHYSICAL ACTIVITY; PRIORITY JOURNAL; QUALITY CONTROL; QUASI EXPERIMENTAL STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK; RISK OF BIAS; RISK REDUCTION; SMOKING CESSATION; SUN PROTECTION BEHAVIOR; SYSTEMATIC REVIEW; EPIDEMIOLOGY; GENETIC PREDISPOSITION; HEALTH EDUCATION; HEALTH LITERACY; META ANALYSIS; PATIENT EDUCATION; PRIMARY PREVENTION; PROCEDURES; PSYCHOLOGY; RISK FACTOR;

GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; HEALTH BEHAVIOR; HEALTH EDUCATION; HEALTH LITERACY; HUMANS; MOTIVATION; PATIENT EDUCATION AS TOPIC; PRIMARY PREVENTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; RISK REDUCTION BEHAVIOR;

EID: 84962584422     PISSN: 09598146     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.i1102     Document Type: Article

References (55)

1. Collins FS, Varmus H. A new initiative on precision medicine. N Engl J Med 2015;372:793-5. doi:10.1056/NEJMp1500523.
2. Allen NE, Sudlow C, Peakman T, Collins R. UK Biobank. UK biobank data: come and get it. Sci Transl Med 2014;6:224ed4. doi:10.1126/ scitranslmed.3008601.
3. Lander ES. Cutting the Gordian helix - regulating genomic testing in the era of precision medicine. N Engl J Med 2015;372:1185-6. doi:10.1056/NEJMp1501964.
4. Collins FS, Green ED, Guttmacher AE, Guyer MS. US National Human Genome Research Institute. A vision for the future of genomics research. Nature 2003;422:835-47. doi:10.1038/nature01626.
5. Collins F. Has the revolution arrived? Nature 2010;464:674-5. doi:10.1038/464674a.
6. Gramling R, Nash J, Siren K, Culpepper L. Predictive genetics in primary care: expectations for the motivational impact of genetic testing affects the importance family physicians place on screening for familial cancer risk. Genet Med 2003;5:172-5. doi:10.1097/01. GIM.0000068986.03217.BB.
7. Dzau VJ, Ginsburg GS, Van Nuys K, Agus D, Goldman D. Aligning incentives to fulfil the promise of personalised medicine. Lancet 2015;385:2118-9. doi:10.1016/S0140-6736(15)60722-X.
8. Chen S, Chaiken S. The heuristic-systematic model in its broader context. In: Chaiken S, Trope Y, eds. Dual process theories in social psychology.Guildford Press, 1999: 73-96.
9. Bates BR, Templeton A, Achter PJ, Harris TM, Condit CM. What does "a gene for heart disease" mean? A focus group study of public understandings of genetic risk factors. Am J Med Genet A 2003;119A:156-61. doi:10.1002/ajmg.a.20113.
10. Shiloh S, Rashuk-Rosenthal D, Benyamini Y. Illness causal attributions: an exploratory study of their structure and associations with other illness cognitions and perceptions of control. J Behav Med 2002;25:373-94. doi:10.1023/A:1015818532390.
11. Senior V, Marteau TM, Weinman J. Impact of genetic testing on causal models of heart disease and arthritis: An analogue study. Psychol Health 2000;14:1077-88. doi:10.1080/08870440008407368.
12. Milne S, Sheeran P, Orbell S. Prediction and intervention in healthrelated behavior: A meta-analytic review of protection motivation theory. J Appl Soc Psychol 2000;30:106-43. doi:10.1111/j.1559-1816.2000. tb02308.x.
13. McClure JB. Are biomarkers useful treatment aids for promoting health behavior change? An empirical review. Am J Prev Med 2002;22:200-7. doi:10.1016/S0749-3797(01)00425-1.
14. Bize R, Burnand B, Mueller Y, Rège-Walther M, Camain JY, Cornuz J. Biomedical risk assessment as an aid for smoking cessation. Cochrane Database Syst Rev 2012;12:CD004705.23235615.
15. Broadstock M, Michie S, Marteau T. Psychological consequences of predictive genetic testing: a systematic review. Eur J Hum Genet 2000;8:731-8. doi:10.1038/sj.ejhg.5200532.
16. Meiser B. Psychological impact of genetic testing for cancer susceptibility: an update of the literature. Psychooncology 2005;14:1060-74. doi:10.1002/pon.933.
17. Beery TA, Williams JK. Risk reduction and health promotion behaviors following genetic testing for adult-onset disorders. Genet Test 2007;11:111-23. doi:10.1089/gte.2006.0527.
18. Heshka JT, Palleschi C, Howley H, Wilson B, Wells PS. A systematic review of perceived risks, psychological and behavioral impacts of genetic testing. Genet Med 2008;10:19-32. doi:10.1097/ GIM.0b013e31815f524f.
19. Scheuner MT, Sieverding P, Shekelle PG. Delivery of genomic medicine for common chronic adult diseases: a systematic review. JAMA 2008;299:1320-34. doi:10.1001/jama.299.11.1320.
20. de Viron S, Van der Heyden J, Ambrosino E, Arbyn M, Brand A, Van Oyen H. Impact of genetic notification on smoking cessation: systematic review and pooled-analysis. PLoS One 2012;7:e40230. doi:10.1371/journal.pone.0040230.
21. Smerecnik C, Grispen JE, Quaak M. Effectiveness of testing for genetic susceptibility to smoking-related diseases on smoking cessation outcomes: a systematic review and meta-analysis. Tob Control 2012;21:347-54. doi:10.1136/tc.2011.042739.
22. Fanshawe TR, Prevost AT, Roberts JS, Green RC, Armstrong D, Marteau TM. Explaining behavior change after genetic testing: the problem of collinearity between test results and risk estimates. Genet Test 2008;12:381-6. doi:10.1089/gte.2007.0103.
23. Burke W, Khoury MJ, Stewart A, Zimmern RL. Bellagio Group. The path from genome-based research to population health: development of an international public health genomics network. Genet Med 2006;8:451-8. doi:10.1097/01.gim.0000228213.72256.8c.
24. Hollands GJ, Hankins M, Marteau TM. Visual feedback of individuals' medical imaging results for changing health behaviour. Cochrane Database Syst Rev 2010;(1):CD007434.20091633.
25. Marteau TM, French DP, Griffin SJ, et al. Effects of communicating DNA-based disease risk estimates on risk-reducing behaviours. Cochrane Database Syst Rev 2010;(10):CD007275.20927756.
26. Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2.The Cochrane Collaboration, 2009.
27. Balshem H, Helfand M, Schünemann HJ, et al. GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol 2011;64:401-6. doi:10.1016/j.jclinepi.2010.07.015.
28. Audrain J, Boyd NR, Roth J, Main D, Caporaso NF, Lerman C. Genetic susceptibility testing in smoking-cessation treatment: one-year outcomes of a randomized trial. Addict Behav 1997;22:741-51. doi:10.1016/S0306-4603(97)00060-9.
29. Lerman C, Gold K, Audrain J, et al. Incorporating biomarkers of exposure and genetic susceptibility into smoking cessation treatment: effects on smoking-related cognitions, emotions, and behavior change. Health Psychol 1997;16:87-99. doi:10.1037/0278-6133.16.1.87.
30. Chao S, Roberts JS, Marteau TM, Silliman R, Cupples LA, Green RC. Health behavior changes after genetic risk assessment for Alzheimer disease: The REVEAL Study. Alzheimer Dis Assoc Disord 2008;22:94-7. doi:10.1097/WAD.0b013e31815a9dcc.
31. Glanz K, Volpicelli K, Kanetsky PA, et al. Melanoma genetic testing, counseling, and adherence to skin cancer prevention and detection behaviors. Cancer Epidemiol Biomarkers Prev 2013;22:607-14. doi:10.1158/1055-9965.EPI-12-1174.
32. Godino JG, van Sluijs EM, Marteau TM, Sutton S, Sharp SJ, Griffin SJ. Effect of communicating genetic and phenotypic risk for type 2 diabetes in combination with lifestyle advice on objectively measured physical activity: protocol of a randomised controlled trial. BMC Public Health 2012;12:444. doi:10.1186/1471-2458-12-444.
33. Grant RW, O'Brien KE, Waxler JL, et al. Personalized genetic risk counseling to motivate diabetes prevention: a randomized trial. Diabetes Care 2013;36:13-9. doi:10.2337/dc12-0884.
34. Hendershot CS, Otto JM, Collins SE, Liang T, Wall TL. Evaluation of a brief web-based genetic feedback intervention for reducing alcohol-related health risks associated with ALDH2. Ann Behav Med 2010;40:77-88. doi:10.1007/s12160-010-9207-3.
35. Hietaranta-Luoma HL, Tahvonen R, Iso-Touru T, Puolijoki H, Hopia A. An intervention study of individual, apoE genotype-based dietary and physical-activity advice: impact on health behavior. J Nutrigenet Nutrigenomics 2014;7:161-74. doi:10.1159/000371743.
36. Hishida A, Terazawa T, Mamiya T, et al. Efficacy of genotype notification to Japanese smokers on smoking cessation - an intervention study at workplace. Cancer Epidemiol 2010;34:96-100. doi:10.1016/j.canep.2009.11.008.
37. Hollands GJ, Whitwell SCL, Parker RA, et al. Effect of communicating DNA based risk assessments for Crohn's disease on smoking cessation: randomised controlled trial. BMJ 2012;345:e4708. doi:10.1136/bmj.e4708.
38. Whitwell SC, Mathew CG, Lewis CM, et al. Trial Protocol: Communicating DNA-based risk assessments for Crohn's disease: a randomised controlled trial assessing impact upon stopping smoking. BMC Public Health 2011;11:44. doi:10.1186/1471-2458-11-44.
39. Ito H, Matsuo K, Wakai K, et al. An intervention study of smoking cessation with feedback on genetic cancer susceptibility in Japan. Prev Med 2006;42:102-8. doi:10.1016/j.ypmed.2005.10.006.
40. Komiya Y, Nakao H, Kuroda Y, Arizono K, Nakahara A, Katoh T. Application of aldehyde dehydrogenase 2 (ALDH2) genetic diagnosis in support of decreasing alcohol intake. J Occup Health 2006;48:161-5. doi:10.1539/joh.48.161.
41. Marteau T, Senior V, Humphries SE, et al. Genetic Risk Assessment for FH Trial Study Group. Psychological impact of genetic testing for familial hypercholesterolemia within a previously aware population: a randomized controlled trial. Am J Med Genet A 2004;128A:285-93. doi:10.1002/ajmg.a.30102.
42. McBride CM, Bepler G, Lipkus IM, et al. Incorporating genetic susceptibility feedback into a smoking cessation program for African-American smokers with low income. Cancer Epidemiol Biomarkers Prev 2002;11:521-8.
43. Meisel SF, Beeken RJ, van Jaarsveld CHM, Wardle J. Genetic susceptibility testing and readiness to control weight: Results from a randomized controlled trial. Obesity (Silver Spring) 2015;23:305-12. doi:10.1002/oby.20958.
44. Meisel SF, Beeken RJ, van Jaarsveld CH, Wardle J. Genetic test feedback with weight control advice: study protocol for a randomized controlled trial. Trials 2012;13:235. doi:10.1186/1745-6215-13-235.
45. Nielsen DE, El-Sohemy A. Disclosure of genetic information and change in dietary intake: a randomized controlled trial. PLoS One 2014;9:e112665. doi:10.1371/journal.pone.0112665.
46. Sanderson SC, Humphries SE, Hubbart C, Hughes E, Jarvis MJ, Wardle J. Psychological and behavioural impact of genetic testing smokers for lung cancer risk: a phase II exploratory trial. J Health Psychol 2008;13:481-94. doi:10.1177/1359105308088519.
47. Voils CI, Coffman CJ, Grubber JM, et al. Does Type 2 Diabetes Genetic Testing and Counseling Reduce Modifiable Risk Factors? A Randomized Controlled Trial of Veterans. J Gen Intern Med 2015;30:1591-8. doi:10.1007/s11606-015-3315-5.
48. Voils CI, Coffman CJ, Edelman D, et al. Examining the impact of genetic testing for type 2 diabetes on health behaviors: study protocol for a randomized controlled trial. Trials 2012;13:121. doi:10.1186/1745-6215-13-121.
49. Weinberg DS, Myers RE, Keenan E, et al. Genetic and environmental risk assessment and colorectal cancer screening in an average-risk population: a randomized trial. Ann Intern Med 2014;161:537-45. doi:10.7326/M14-0765.
50. Myers RE, Manne SL, Wilfond B, et al. A randomized trial of genetic and environmental risk assessment (GERA) for colorectal cancer risk in primary care: trial design and baseline findings. Contemp Clin Trials 2011;32:25-31. doi:10.1016/j.cct.2010.08.013.
51. West R, Hajek P, Stead L, Stapleton J. Outcome criteria in smoking cessation trials: proposal for a common standard. Addiction 2005;100:299-303. doi:10.1111/j.1360-0443.2004.00995.x.
52. Bloss CS, Schork NJ, Topol EJ. Effect of direct-to-consumer genomewide profiling to assess disease risk. N Engl J Med 2011;364:524-34. doi:10.1056/NEJMoa1011893.
53. Marteau TM, Weinman J. Self-regulation and the behavioural response to DNA risk information: a theoretical analysis and framework for future research. Soc Sci Med 2006;62:1360-8. doi:10.1016/j. socscimed.2005.08.005.
54. Evans JP, Meslin EM, Marteau TM, Caulfield T. Genomics. Deflating the genomic bubble. Science 2011;331:861-2. doi:10.1126/science.1198039.
55. Academy of Medical Sciences. Realising the potential of stratified medicine.Academy of Medical Sciences, 2013.